1. Home
  2. DSL vs MNKD Comparison

DSL vs MNKD Comparison

Compare DSL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DoubleLine Income Solutions Fund of Beneficial Interests

DSL

DoubleLine Income Solutions Fund of Beneficial Interests

N/A

Current Price

$10.54

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo MannKind Corporation

MNKD

MannKind Corporation

N/A

Current Price

$4.04

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DSL
MNKD
Founded
2013
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2013
2004

Fundamental Metrics

Financial Performance
Metric
DSL
MNKD
Price
$10.54
$4.04
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$8.69
AVG Volume (30 Days)
546.7K
3.7M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
11.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$348,966,000.00
Revenue This Year
N/A
$35.81
Revenue Next Year
N/A
$11.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.23
52 Week Low
$10.49
$2.23
52 Week High
$12.67
$6.51

Technical Indicators

Market Signals
Indicator
DSL
MNKD
Relative Strength Index (RSI) 43.23 50.66
Support Level $10.53 $3.74
Resistance Level $11.02 $4.23
Average True Range (ATR) 0.10 0.15
MACD -0.00 -0.01
Stochastic Oscillator 12.27 38.76

Price Performance

Historical Comparison
DSL
MNKD

About DSL DoubleLine Income Solutions Fund of Beneficial Interests

DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: